In vivo evidence of gamma-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer

gamma-Tocotrienol (gammaT3) is known to selectively kill prostate cancer (PCa) cells and to sensitize the cells to docetaxel (DTX)-induced apoptosis. In the present study, the pharmacokinetics of gammaT3 and the in vivo cytotoxic response of androgen-independent prostate cancer (AIPCa) tumor following gammaT3 treatment were investigated. Here, we investigated these antitumor effects for PCa tumors in vivo. The pharmacokinetic and tissue distribution of gammaT3 after exogenous gammaT3 supplementation were examined. Meanwhile, the response of the tumor to gammaT3 alone or in combination with DTX were studied by real-time in vivo bioluminescent imaging and by examination of biomarkers associated with cell proliferation and apoptosis. After intraperitoneal injection, gammaT3 rapidly disappeared from the serum and was selectively deposited in the AIPCa tumor cells. Administration of gammaT3 alone for 2 weeks resulted in a significant shrinkage of the AIPCa tumors. Meanwhile, further inhibition of the AIPCa tumor growth was achieved by combined treatment of gammaT3 and DTX (p < 0.002). The in vivo cytotoxic antitumor effects induced by gammaT3 seem to be associated with a decrease in expression of cell proliferation markers (proliferating cell nuclear antigen, Ki-67 and Id1) and an increase in the rate of cancer cell apoptosis [cleaved caspase 3 and poly(ADP-ribose) polymerase]. Additionally, the combined agents may be more effective at suppressing the invasiveness of AIPCa. Overall, our results indicate that gammaT3, either alone or in combination with DTX, may provide a treatment strategy that can improve therapeutic efficacy against AIPCa while reducing the toxicity often seen in patients treated with DTX.

Over expression of ID-1 in prostate cancer

PURPOSE

The helix-loop-helix protein Id-1 serves to prevent basic helix-loop-helix transcription factors from binding to DNA, thus, inhibiting the transcription of differentiation associated genes. Over expression of Id-1 has been reported in certain tumors, such as breast, esophageal, pancreatic and medullary thyroid cancers. In Noble rats we have previously demonstrated that up-regulation of Id-1 is closely associated with the development of sex hormone induced prostate cancers. Therefore, we hypothesized that over expression of Id-1 would also occur in human prostate cancer and Id-1 protein may serve as a potential marker for prostate carcinogenesis. To test this hypothesis we analyzed Id-1 messenger RNA and protein expression by in situ hybridization and immunohistochemical study in human normal prostate, benign prostatic hyperplasia (BPH) and prostate cancer tissues.

MATERIALS AND METHODS

Pathological specimens were obtained from 19 patients with BPH and 47 with prostate carcinoma, representing a complete range of Gleason grades. A total of 12 normal prostate tissue specimens were used for comparison. Immunohistochemical study was performed using the polyclonal antibody against human Id-1 protein and an RNA probe was generated from Id-1 complementary DNA for in situ hybridization.

RESULTS

Negative to weak expression of Id-1 in normal prostate or BPH tissue was observed on immunohistochemical study and in situ hybridization. In contrast, all prostate cancer biopsies showed significant positive Id-1 expression in tumor cells at the messenger RNA and protein levels. Furthermore, Id-1 expression was stronger in poorly differentiated than in well differentiated carcinomas, suggesting that the level of Id-1 expression may be associated with tumor malignancy.

CONCLUSIONS

Our results suggest that over expression of Id-1 may have important roles in the development of prostate cancer. The potential use of Id-1 protein as a marker for prostate cancer should be further explored.